American Heart Journal
Volume 148, Issue 6 , Pages 1068-1078 , December 2004

Challenges in the conduct of large simple trials of important generic questions in resource-poor settings: The CREATE and ECLA trial program evaluating GIK (glucose, insulin and potassium) and low-molecular-weight heparin in acute myocardial infarction

  • Salim Yusuf, DPhil, FRCPC

      Affiliations

    • Department of Medicine, McMaster University, and Population Health Research Institute (PHRI), Hamilton General Hospital, McMaster University, Hamilton, Canada
    • Corresponding Author InformationReprint requests: Salim Yusuf, DPhil, FRCPC, Population Health Research Institute, Hamilton General Hospital and McMaster University, 237 Barton Street East, Hamilton, Ontario, Canada L8L 2X2.
    • ,
  • Shamir R. Mehta, MD, MSc, FRCPC, FACC

      Affiliations

    • Department of Medicine, McMaster University, and Population Health Research Institute (PHRI), Hamilton General Hospital, McMaster University, Hamilton, Canada
    • ,
  • Rafael Díaz, MD

      Affiliations

    • Estudios Clínicos LatinoAmerica (ECLA), and the Department of Cardiology, Instituto Cardiovascular de Rosario (ICR), Rosario, Santa Fe, Argentina
    • ,
  • Ernesto Paolasso, MD

      Affiliations

    • Estudios Clínicos LatinoAmerica (ECLA), and the Department of Cardiology, Instituto Cardiovascular de Rosario (ICR), Rosario, Santa Fe, Argentina
    • ,
  • Prem Pais, MBBS

      Affiliations

    • St. John's Medical College and the Division of Clinical Research, Institute of Population Health and Clinical Research, St. John's National Academy of Health Sciences, Bangalore, India
    • ,
  • Denis Xavier, MBBS

      Affiliations

    • St. John's Medical College and the Division of Clinical Research, Institute of Population Health and Clinical Research, St. John's National Academy of Health Sciences, Bangalore, India
    • ,
  • Changchun Xie, PhD

      Affiliations

    • Population Health Research Institute (PHRI), McMaster University, Hamilton, Canada
    • ,
  • Rashid J. Ahmed, BScH

      Affiliations

    • Population Health Research Institute (PHRI), McMaster University, Hamilton, Canada
    • ,
  • Khawar Khazmi, MBBS

      Affiliations

    • Cardiology Section, Department of Medicine, Aga Khan University Hospital, Karachi, Pakistan
    • ,
  • Jun Zhu, MD

      Affiliations

    • Fu Wai Hospital, Beijing, China
    • ,
  • Lisheng Liu, MD

      Affiliations

    • Cardiovascular Institute and Fu Wai Hospital (CAMS), and Clinical Trials and Research Centre, Chinese Hypertension League Institute, Beijing, China
    • ,
  • CREATE-ECLA Investigators and Steering Committee

References 

  1. Yusuf S, Reddy S, Ounpuu S, et al.  Global burden of cardiovascular diseases: part I: general considerations, the epidemiologic transition, risk factors, and impact of urbanization. Circulation. 2001;104:2746–2753
  2. Yusuf S, Wittes J, Friedman L. Overview of results of randomized clinical trials in heart disease (I. Treatments following myocardial infarction). JAMA. 1988;260:2088–2093
  3. Keeley EC, Boura JA, Grines CL. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. Lancet. 2003;361:13–20
  4. The GUSTO Investigators . Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: the GUSTO V randomised trial. Lancet. 2001;357:1905–1914
  5. White H  Hirulog and Early Reperfusion or Occlusion (HERO)-2 Trial Investigators . Thrombin-specific anticoagulation with bivalirudin versus heparin in patients receiving fibrinolytic therapy for acute myocardial infarction: the HERO-2 randomised trial. Lancet. 2001;358:1855–1863
  6. The GUSTO Investigators . An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med. 1993;329:673–682
  7. ISIS-3 (Third International Study of Infarct Survival) Collaborative group . ISIS-3: a randomized comparison of streptokinase vs tissue plasminogen activator vs anistreplase and of aspirin plus heparin vs aspirin alone among 41 229 cases of suspected acute myocardial infarction. Lancet. 1992;339:754–769
  8. Gruppo Italiano Per Lo Studio Della Sopravvivenza Nell'Infarto Miocardico . GISSI-2: a factorial randomized trial of alteplase versus streptokinase and heparin versus no heparin among 12 490 patients with acute myocardial infarction. Lancet. 1990;336:65–71
  9. Kontny F, Dale J, Abildgaard U, et al.  FRAMI study group   Randomized trial of low molecular weight heparin (dalteparin) in prevention of left ventricular thrombus formation and arterial embolism after acute anterior myocardial infarction: the Fragmin in Acute Myocardial Infarction (FRAMI) Study. J Am Coll Cardiol. 1997;30:962–969
  10. Glick A, Kornowski R, Michowich Y, et al.  Reduction of reinfarction and angina with use of low-molecular-weight heparin therapy after streptokinase (and heparin) in acute myocardial infarction. Am J Cardiol. 1996;77:1145–1148
  11. Frostfeldt G, Ahlberg G, Gustafsson G, et al.  Low-molecular-weight heparin (dalteparin) as adjuvant treatment to thrombolysis in acute myocardial infarction—a pilot study: biochemical markers in acute coronary syndromes (BIOMACS II). J Am Coll Cardiol. 1999;33:627–633
  12. Simoons M, Krzeminska-Pakula M, Alonso A, et al.  Improved reperfusion and clinical outcome with enoxaparin as an adjunct to streptokinase thrombolysis in acute myocardial infarction (The AMI-SK study). Eur Heart J. 2002;23:1282–1290
  13. Baird SH, McBride SJ, Trouton TG, et al.  Low molecular weight heparin versus unfractionated heparin following thrombolysis in myocardial infarction. J Am Coll Cardiol. 1998;31:191A
  14. Ross AM, Molhoek P, Lundergan C, et al.  Randomized comparison of enoxaparin, a low-molecular-weight heparin, with unfractionated heparin adjunctive to recombinant tissue plasminogen activator thrombolysis and aspirin: second trial of Heparin and Aspirin Reperfusion Therapy (HART II). Circulation. 2001;104:648–652
  15. Cohen M, Gensini GF, Maritz F, et al.  The safety and efficacy of subcutaneous enoxaparin versus intravenous unfractionated heparin and tirofiban versus placebo in the treatment of acute ST-segment elevation myocardial infarction patients ineligible for reperfusion (TETAMI): a randomized trial. J Am Coll Cardiol. 2003;42:1348–1356
  16. Antman EM, Louwerenburg HW, Baars HF, et al.  Enoxaparin as adjunctive antithrombin therapy for ST-elevation myocardial infarction: results of the ENTIRE-Thrombolysis in Myocardial Infarction (TIMI) 23 Trial. Circulation. 2002;105:1642–1649 Erratum in: Circulation 2002 Jun 11;105:2799
  17. The Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 Investigators . Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction. Lancet. 2001;358:605–613
  18. Wallentin L, Goldstein P, Armstrong PW, et al.  Efficacy and safety of tenecteplase in combination with the low-molecular-weight heparin enoxaparin or unfractionated heparin in the prehospital setting: the Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 PLUS randomized trial in acute myocardial infarction. Circulation. 2003;108:135–142
  19. Mittra B. Potassium, glucose, and insulin in treatment of myocardial infarction. Lancet. 1965;2:607–609
  20. Pilcher J, Etishamudin M, Exon P, et al.  Potassium, glucose and insulin in myocardial infarction. Lancet. 1967;1:1109
  21. Pentecost BL, Mayne NM, Lamb P. Controlled trial of intravenous glucose, potassium, and insulin in acute myocardial infarction. Lancet. 1968;1:946–948
  22. Medical Research Council Working Party on the Treatment of Myocardial Infarction . Potassium, glucose, and insulin treatment for acute myocardial infarction. Lancet. 1968;2:1355–1360
  23. Hjermann I. A controlled study of peroral glucose, insulin and potassium treatment in myocardial infarction. Acta Med Scand. 1971;190:213–218
  24. Heng MK, Norris RM, Singh BN, et al.  Effects of glucose and glucose-insulin-potassium on haemodynamics and enzyme release after acute myocardial infarction. Br Heart J. 1977;39:748–757
  25. Stanley AWH, Prather JW. Glucose-insulin-potassium, patient mortality and the acute myocardial infarction: results from a prospective randomized study. Circulation. 1978;57(suppl II):II, 62; Abstract
  26. Rogers WJ, McDaniel HG, Mantle JA, et al.  Prospective randomized trial of glucose-insulin-potassium in acute myocardial infarction: effects of hemodynamics, short and long-term survival. J Am Coll Cardiol. 1983;1:628
  27. Mantle JA, Rogers WJ, Smith R, et al.  Clinical effects of glucose-insulin-potassium on left ventricular function in acute myocardial infarction: results from a randomized clinical trial. Am Heart J. 1981;102:313–324
  28. Whitlow PL, Rogers WJ, Smith LR, et al.  Enhancements of left ventricular function by glucose-insulin-potassium infusion in acute myocardial infarction. Am J Cardiol. 1982;49:811–820
  29. Salter LF, Green CE, Kent KM, et al.  Metabolic support during coronary reperfusion. Am Heart J. 1987;114:54–58
  30. Malmberg K, Ryden L, Efendic S, et al.  Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI Study): effect on mortality at 1 year. J Am Coll Cardiol. 1995;26:57–65
  31. Díaz R, Paolasso EA, Piegas LS, et al.  Metabolic modulation of acute myocardial infarction: the ECLA glucose-insulin-potassium pilot trial. Circulation. 1998;98:2227–2234
  32. Ceremuzynski L, Budaj A, Czepiel A, et al.  Low-dose glucose-insulin-potassium is ineffective in acute myocardial infarction: results of a randomized multicenter pol-GIK trial. Cardiovascular Drugs and Therapy. 1999;13:191–200
  33. Diaz-Araya G, Nettle D, Castro P, et al.  Oxidative stress after reperfusion with primary coronary angioplasty: lack of effect of glucose-insulin-potassium infusion. Crit Care Med. 2002;30:417–421
  34. van der Horst IC, Zijlstra F, van't Hof AW, et al.  Glucose-insulin-potassium infusion in patients treated with primary angioplasty for acute myocardial infarction: the glucose-insulin-potassium study: a randomized trial. J Am Coll Cardiol. 2003;42:784–791
  35. Yusuf S, Peto R, Lewis J, et al.  Beta blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis. 1985;XXVII:335–371
  36. Mehta SR. The CREATE Study : rationale, design and methods. July 2002. MS Thesis, McMaster University, Hamilton, Canada

☆ Salim Yusuf is supported by an Endowed Chair of the Heart and Stroke Foundation of Ontario and a Senior Scientist Award from the Canadian Institutes of Health Research (CIHR). Shamir R. Mehta is supported by a CIHR New Investigator award.

PII: S0002-8703(04)00593-9

doi: 10.1016/j.ahj.2004.08.033

American Heart Journal
Volume 148, Issue 6 , Pages 1068-1078 , December 2004

Article Tools

* Image Usage & Resolution